4.24
price up icon1.92%   0.08
after-market Dopo l'orario di chiusura: 4.24
loading
Precedente Chiudi:
$4.16
Aprire:
$4.21
Volume 24 ore:
108.88K
Relative Volume:
0.83
Capitalizzazione di mercato:
$242.47M
Reddito:
$34.16M
Utile/perdita netta:
$-98.43M
Rapporto P/E:
-1.812
EPS:
-2.34
Flusso di cassa netto:
$-119.33M
1 W Prestazione:
-2.75%
1M Prestazione:
+23.98%
6M Prestazione:
-48.92%
1 anno Prestazione:
-30.61%
Intervallo 1D:
Value
$4.08
$4.34
Intervallo di 1 settimana:
Value
$4.00
$4.51
Portata 52W:
Value
$2.9448
$10.25

Foghorn Therapeutics Inc Stock (FHTX) Company Profile

Name
Nome
Foghorn Therapeutics Inc
Name
Telefono
617-586-3100
Name
Indirizzo
500 TECHNOLOGY SQUARE, CAMBRIDGE
Name
Dipendente
112
Name
Cinguettio
Name
Prossima data di guadagno
2025-03-07
Name
Ultimi documenti SEC
Name
FHTX's Discussions on Twitter

Confronta FHTX con altri titoli

Azioni Prezzo Cap. di mercato Reddito Reddito netto Flusso di cassa EPS
Biotechnology icon
FHTX
Foghorn Therapeutics Inc
4.24 242.47M 34.16M -98.43M -119.33M -2.34
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
501.15 126.96B 11.02B -535.60M -978.00M -2.20
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
605.61 65.06B 14.09B 4.50B 2.96B 39.28
Biotechnology icon
ARGX
Argen X Se Adr
649.67 37.54B 2.19B 833.04M -1.28B 12.71
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
259.39 32.56B 2.25B -278.16M -42.59M -2.17
Biotechnology icon
ONC
Beigene Ltd Adr
255.77 26.40B 3.81B -644.79M -669.77M -6.24

Foghorn Therapeutics Inc Stock (FHTX) Upgrades & Downgrades

Data Azione Analista Modifica della valutazione
2025-04-23 Iniziato Citizens JMP Mkt Outperform
2025-01-30 Iniziato B. Riley Securities Buy
2024-09-03 Iniziato Jefferies Buy
2024-08-19 Iniziato Evercore ISI Outperform
2023-03-28 Iniziato BofA Securities Buy
2023-01-05 Iniziato BMO Capital Markets Outperform
2021-11-22 Iniziato H.C. Wainwright Buy
2020-11-17 Iniziato Cowen Outperform
2020-11-17 Iniziato Goldman Buy
2020-11-17 Iniziato Morgan Stanley Overweight
2020-11-17 Iniziato Wedbush Outperform
Mostra tutto

Foghorn Therapeutics Inc Borsa (FHTX) Ultime notizie

pulisher
03:22 AM

JMP Securities Reiterates Market Outperform Rating for Foghorn Therapeutics (NASDAQ:FHTX) - Defense World

03:22 AM
pulisher
May 01, 2025

Foghorn Therapeutics expands board with biotech veterans By Investing.com - Investing.com India

May 01, 2025
pulisher
May 01, 2025

Foghorn Therapeutics expands board with biotech veterans - Investing.com

May 01, 2025
pulisher
May 01, 2025

Foghorn Therapeutics Appoints Neil Gallagher and Stuart Duty to its Board of Directors - GlobeNewswire

May 01, 2025
pulisher
May 01, 2025

Foghorn Therapeutics Appoints Neil Gallagher and Stuart Duty to its Board of Directors - GlobeNewswire Inc.

May 01, 2025
pulisher
Apr 29, 2025

Foghorn Therapeutics Presents New Preclinical Data on Selective - GuruFocus

Apr 29, 2025
pulisher
Apr 29, 2025

Geode Capital Management LLC Boosts Stake in Foghorn Therapeutics Inc. (NASDAQ:FHTX) - Defense World

Apr 29, 2025
pulisher
Apr 28, 2025

FHTX Unveils Promising Preclinical Data at Cancer Research Confe - GuruFocus

Apr 28, 2025
pulisher
Apr 28, 2025

Foghorn Therapeutics Presents Preclinical Data at AACR 2025 - TipRanks

Apr 28, 2025
pulisher
Apr 28, 2025

Foghorn Therapeutics Presents New Preclinical Data on - GlobeNewswire

Apr 28, 2025
pulisher
Apr 28, 2025

Breakthrough Cancer Drug FHD-909 Shows Synergy with Leading Treatments in Lung Cancer Studies - Stock Titan

Apr 28, 2025
pulisher
Apr 26, 2025

Foghorn Therapeutics (NASDAQ:FHTX) Research Coverage Started at JMP Securities - Defense World

Apr 26, 2025
pulisher
Apr 26, 2025

Foghorn Therapeutics (NASDAQ:FHTX) Earns Mkt Outperform Rating from Analysts at Citizens Jmp - Defense World

Apr 26, 2025
pulisher
Apr 23, 2025

This PayPal Analyst Begins Coverage On A Bearish Note; Here Are Top 5 Initiations For Wednesday - Benzinga

Apr 23, 2025
pulisher
Apr 23, 2025

JMP Securities Initiates Coverage of Foghorn Therapeutics (FHTX) with Market Outperform Recommendation - Nasdaq

Apr 23, 2025
pulisher
Apr 23, 2025

Foghorn Therapeutics (FHTX) Gains Outperform Rating with $9 Targ - GuruFocus

Apr 23, 2025
pulisher
Apr 23, 2025

Foghorn Therapeutics (FHTX) Gains Outperform Rating with $9 Target | FHTX Stock News - GuruFocus

Apr 23, 2025
pulisher
Apr 18, 2025

Brokerages Set Foghorn Therapeutics Inc. (NASDAQ:FHTX) Price Target at $13.17 - Defense World

Apr 18, 2025
pulisher
Apr 15, 2025

Foghorn Therapeutics to Host Virtual Investor Event to Review Pi - GuruFocus

Apr 15, 2025
pulisher
Apr 15, 2025

Foghorn Therapeutics to Host Virtual Investor Event to Review Pipeline Updates in Conjunction with 2025 AACR Annual Meeting | FHTX Stock News - GuruFocus

Apr 15, 2025
pulisher
Apr 15, 2025

Foghorn Therapeutics to Host Virtual Investor Event to - GlobeNewswire

Apr 15, 2025
pulisher
Apr 15, 2025

Major Pipeline Breakthrough: Foghorn's First-in-Class Cancer Drug Shows Promise in NSCLC Treatment - Stock Titan

Apr 15, 2025
pulisher
Apr 15, 2025

Foghorn Therapeutics Inc. (NASDAQ:FHTX) Shares Bought by Wellington Management Group LLP - Defense World

Apr 15, 2025
pulisher
Apr 15, 2025

Foghorn Therapeutics (NASDAQ:FHTX) Trading 4.1% Higher – Time to Buy? - Defense World

Apr 15, 2025
pulisher
Apr 09, 2025

Foghorn Therapeutics Inc. (NASDAQ:FHTX) Shares May Have Slumped 29% But Getting In Cheap Is Still Unlikely - simplywall.st

Apr 09, 2025
pulisher
Apr 07, 2025

(FHTX) Technical Data - news.stocktradersdaily.com

Apr 07, 2025
pulisher
Apr 02, 2025

Foghorn Therapeutics Inc. (FHTX) Reports Q4 Loss, Lags Revenue Estimates - MSN

Apr 02, 2025
pulisher
Mar 27, 2025

Trend Tracker for (FHTX) - news.stocktradersdaily.com

Mar 27, 2025
pulisher
Mar 26, 2025

Foghorn: SMARCA4 Targeting Brings About Treating Up To 10% Of NSCLC Patients (NASDAQ:FHTX) - Seeking Alpha

Mar 26, 2025
pulisher
Mar 26, 2025

Foghorn Therapeutics Inc. (NASDAQ:FHTX) Given Consensus Recommendation of “Buy” by Brokerages - The AM Reporter

Mar 26, 2025
pulisher
Mar 25, 2025

Foghorn Therapeutics Announces New Preclinical Data for - GlobeNewswire

Mar 25, 2025
pulisher
Mar 25, 2025

Breakthrough Cancer Drug FHD-909 Reveals Powerful Combination Potential Against Lung Cancer - Stock Titan

Mar 25, 2025
pulisher
Mar 24, 2025

Analysts Set Foghorn Therapeutics Inc. (NASDAQ:FHTX) Target Price at $13.17 - Defense World

Mar 24, 2025
pulisher
Mar 22, 2025

2,029,383 Shares in Foghorn Therapeutics Inc. (NASDAQ:FHTX) Bought by Raymond James Financial Inc. - Defense World

Mar 22, 2025
pulisher
Mar 20, 2025

Foghorn Therapeutics adjusts ATM offering to $100M By Investing.com - Investing.com Australia

Mar 20, 2025
pulisher
Mar 20, 2025

Foghorn Therapeutics adjusts ATM offering to $100M - Investing.com

Mar 20, 2025
pulisher
Mar 18, 2025

Research Analysts Offer Predictions for FHTX Q1 Earnings - The AM Reporter

Mar 18, 2025
pulisher
Mar 18, 2025

What is B. Riley’s Forecast for FHTX Q1 Earnings? - Defense World

Mar 18, 2025
pulisher
Mar 13, 2025

Foghorn Therapeutics Reports Progress and Financial Stability - TipRanks

Mar 13, 2025
pulisher
Mar 11, 2025

Rhumbline Advisers Purchases 3,049 Shares of Foghorn Therapeutics Inc. (NASDAQ:FHTX) - Defense World

Mar 11, 2025
pulisher
Mar 10, 2025

Foghorn Therapeutics’ (FHTX) “Buy” Rating Reiterated at HC Wainwright - Defense World

Mar 10, 2025
pulisher
Mar 07, 2025

Promising Advancements and Strategic Collaborations Position Foghorn Therapeutics as a Strong Buy - TipRanks

Mar 07, 2025
pulisher
Mar 07, 2025

Promising Potential of Foghorn Therapeutics’ FHD-909 Drives Buy Rating Amid Strategic Advances - TipRanks

Mar 07, 2025
pulisher
Mar 06, 2025

Foghorn Therapeutics Inc. reports results for the quarter ended December 31Earnings Summary - TradingView

Mar 06, 2025
pulisher
Mar 06, 2025

Foghorn Therapeutics 2024 Net Loss Narrows, Revenue Declines -- Shares Slipping Late - Marketscreener.com

Mar 06, 2025
pulisher
Mar 06, 2025

Foghorn Therapeutics Continues Enrollment in Phase 1 Trial of First-in-Class SMARCA2 Inhibitor FHD-909 for NSCLC and Reports Strong Financial Outlook - Nasdaq

Mar 06, 2025
pulisher
Mar 06, 2025

Foghorn Therapeutics Provides Financial Update for 2024 and 2025 Strategic Outlook - GlobeNewswire

Mar 06, 2025
pulisher
Mar 06, 2025

Can Foghorn's $243M War Chest Transform Cancer Treatment? Key Pipeline Updates - StockTitan

Mar 06, 2025
pulisher
Mar 01, 2025

Will Foghorn Therapeutics Inc. (FHTX) Report Negative Q4 Earnings? What You Should Know - MSN

Mar 01, 2025
pulisher
Feb 28, 2025

Institutional investors may adopt severe steps after Foghorn Therapeutics Inc.'s (NASDAQ:FHTX) latest 14% drop adds to a year losses - Yahoo

Feb 28, 2025
pulisher
Feb 27, 2025

Foghorn Therapeutics (FHTX) Projected to Post Quarterly Earnings on Thursday - Defense World

Feb 27, 2025

Foghorn Therapeutics Inc Azioni (FHTX) Dati Finanziari

Reddito

loading

Reddito netto

loading

Flusso di cassa

loading

EPS

loading
$72.30
price down icon 0.47%
$21.48
price up icon 2.63%
$32.89
price up icon 1.26%
$27.90
price up icon 13.09%
$104.94
price up icon 2.45%
biotechnology ONC
$255.77
price up icon 0.05%
Capitalizzazione:     |  Volume (24 ore):